Clinical trial
The Role of Multimodal Imaging and Circulating Biomarkers in Predicting the Response of Neoadjuvant Chemotherapy for Breast Cancer
NCT03242551 is registered in ClinicalTrials.gov with Shenzhen People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Role of Multimodal Imaging and Circulating Biomarkers in Predicting the Response of Neoadjuvant Chemotherapy for Breast Cancer
- Lead sponsor
- Shenzhen People's Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- November 8, 2017
- Completion date
- December 31, 2022
- Enrollment
- 120 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.